In BRAF-mutated melanoma, the response rate to BRAF and MEK inhibition was 67–69% [1,2,3] and 68–70% [4,5] with first-line dabrafenib + trametinib and vemurafenib + cobimetinib, respectively; and 63% with encorafenib + binimetinib in previously untreated patients or who progressed after previous ICI [6]. This evidence concerns the gene BRAF and melanoma.